PRESS RELEASE published on 09/17/2025 at 07:30, 8 months 6 days ago Informations privilégiées / Information sur chiffre d’affaires annuel MaaT Pharma publie ses résultats semestriels 2025 et réalise un point sur ses activités, incluant des résultats positifs d'essais cliniques et des accords stratégiques, renforçant sa position financière et opérationnelle Résultats Semestriels Essais Cliniques Position Financière MaaT Pharma Accords Stratégiques
PRESS RELEASE published on 09/17/2025 at 07:30, 8 months 6 days ago Inside Information / Information on annual revenues MaaT Pharma presents positive Half Year 2025 Results with promising data from Phase 3 trial of MaaT013 in aGvHD. Company strengthens position with partnerships and financing Partnerships Phase 3 Trial Half Year Results MaaT Pharma AGvHD
BRIEF published on 07/28/2025 at 07:35, 9 months 26 days ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
BRIEF published on 07/28/2025 at 07:35, 9 months 26 days ago MaaT Pharma obtient un prêt de 37,5 millions d'euros pour dynamiser ses programmes d'hémato-oncologie Développement Clinique Prêt De La BEI Hémato-oncologie Thérapie Du Microbiome Approbation De Xervyteg®
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 26 days ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 26 days ago Informations privilégiées / Autres communiqués MaaT Pharma obtient 37,5 millions d'euros de la Banque Européenne d'Investissement pour soutenir ses programmes cliniques en hémato-oncologie. Financement structuré par tranches pour diversifier les sources de financement Financement Banque Européenne D'investissement MaaT Pharma Biotechnologies Hémato-oncologie
BRIEF published on 06/24/2025 at 20:05, 10 months 29 days ago Assemblée Générale de MaaT Pharma : Résultats et Nominations Kepler Cheuvreux Assemblée Générale Resolutions MaaT Pharma Nomination Président
BRIEF published on 06/24/2025 at 20:05, 10 months 29 days ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 10 months 29 days ago Informations privilégiées / Autres communiqués MaaT Pharma présente les résultats de son Assemblée Générale ordinaire annuelle et extraordinaire avec un quorum dépassant 73%. Résolutions approuvées concernant les comptes et la gouvernance Gouvernance Assemblée Générale Résultats MaaT Pharma Comptes
PRESS RELEASE published on 06/24/2025 at 20:00, 10 months 29 days ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
Published on 05/23/2026 at 19:45, 9 hours 57 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 2 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:35, 6 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 13 hours 11 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 45 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:35, 1 day 10 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
